The purpose of this study is to find the highest dose of the drug vorinostat that can be given safely with standard chemotherapy in patients with HIV-related diffuse large B-cell lymphoma (DLBCL). Vorinostat is approved for the treatment of another type of lymphoma called cutaneous T-cell lymphoma, but its use for DLBCL is considered investigational.
Patients will receive vorinostat with either rituximab and CHOP therapy (for those with low-risk DLBCL) or vorinostat with rituximab and EPOCH therapy (for patients with high-risk disease). Adding vorinostat to standard therapy may improve the treatment for this type of lymphoma.
Vorinostat may also have a positive effect against HIV and other viruses which can cause lymphoma. Doctors will be monitoring the effect of this treatment on HIV and other viruses in the blood.